Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Colin Galbraith
Person

Colin Galbraith

Tracked across 2 events · 26 articles · First seen Aug 03, 2026 · Last active Aug 17, 2026

Sentiment
0
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 0
Business
AstraZeneca discontinues volrustomig lung cancer trial
AstraZeneca announced on August 17, 2026, that it is discontinuing the Phase III EVOLVE-Lung02 trial of volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC). The decision followed a recommendation from an…
Impact: Colin Galbraith, AstraZeneca's executive vice president for oncology R&D, commented on the trial discontinuation, expressing disappointment and commitment to learning from the trial.
Aug 17, 2026 · 20 articles
0 0
Regulatory
NatureScot refuses guga hunt licence
Impact: Colin Galbraith, chairman of United Kingdom — NatureScot, thanked officials for handling the licence application professionally.
Aug 03, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Colin Galbraith live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.